Use of carvedilol in the treatment of heart failure

Hospital Medicine

Volumn 64, Issue 5, 2003, Pages 288-291

  Coats, Andrew ^a  

^a University of Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; METOPROLOL; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

BRADYCARDIA; CLINICAL TRIAL; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FLUID RETENTION; HEALTH CARE COST; HEART FAILURE; HUMAN; HYPOTENSION; LOW DRUG DOSE; META ANALYSIS; PRIMARY HEALTH CARE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TABLET; TREATMENT OUTCOME; CHRONIC DISEASE; FORWARD HEART FAILURE;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; CARDIAC OUTPUT, LOW; CHRONIC DISEASE; HUMANS; PROPANOLAMINES;

EID: 0038205522     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2003.64.5.1761     Document Type: Review

References (13)

1. Bonet S, Agusti A, Arnau JM et al (2000) β-adrenergic blocking agents in heart failure. Benefits of vasodilating and nonvasodilating agents according to patients' characteristics: A meta-analysis of clinical trials. Arch Intern Med 160: 621-7
2. Cleland JGF, McGowan J, Clark A, Freemantle N (1999) The evidence for beta-blockers in heart failure. Br Med J 318: 824-5
3. Dargie HJ (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 357: 1385-9
4. Department of Health (2000) National Service Framework for Coronary Heart Disease. Department of Health, London
5. Goldstein S, Gottlieb SS (2002) The impact of beta-blockade on mortality rates in patients with congestive heart failure. J Card Fail 6(suppl 1): 15-24
6. Hobbs FDR, Davis RC, Lip GYH (2000) Heart failure in general practice. Br Med J 320: 626-9
7. Hunt SA, Baker DW, Chin MH et al (2001) ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration with the International Society for Heart transplantations; Endorsed by the Heart Failure Society of America. Circulation 104: 2996-3007
8. Lechat P, Packer M, Chalon S et al (1998) Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo controlled, randomized trials. Circulation 98: 1184-91
9. McMurray J, Cohen-Solal A, Dietz R et al (2001) Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Failure 3: 495-502
10. Packer M, Colucci WS, Sackner-Bernstein JD et al (1996) Double-blind placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial. Circulation 94: 2799
11. Packer M , Coats AJ, Fowler MB et al for the CarvedilOl ProspEctive ranNdomIzed CUmulative Survival (COPERNICUS) study group (2001) Effect of carvedilol on survival in serve chronic heart failure. N Engl J Med 344: 1651-66
12. Petersen S, Rayner M (2002) Coronary Heart Disease Statistics: Heart Failure Supplement. British Heart Foundation, London
13. Remme WJ (2002) Carvedilol ACE Inhibitor Remodelling Mild CHF Evaluation trial. European Society of Cardiology Congress, Berlin (3 September): Hotline III: 2505